NovaBay Pharma (NBY) Tops Q4 EPS by 3c

NovaBay Pharma (NYSE: NBY) reported Q4 EPS of ($0.02), $0.03 better than the analyst estimate of ($0.05). Revenue for the quarter came in at $2.6 million versus the consensus estimate of $3.34 million.

For earnings history and earnings-related data on NovaBay Pharma (NBY) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Pro Diversity Network (IPDN) Reports Q2 Loss of $0.15
• Star Equity Holdings (STRR) Misses Q2 EPS by 8c